Fall Clinical News: Deuruxolitinib Shows Early and Sustained Efficacy in AA
New research adds to a growing body of evidence supporting the safety and efficacy of deuruxolitinib (Leqselvi, Sun Pharma) in alopecia areata (AA). Taken together, the studies, which were presented at the 2025 Fall Clinical Dermatology Conference in Las Vegas, NV, show early efficacy that is sustained and also holds across subgroups. “Deuruxolitinib represents a […]